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A number of linear and cyclic peptides containing alternative arginine and cysteine residues,
namely linear (CR) 3, linear (CR)4, linear (CR)5, cyclic [CR]4, and cyclic [CR]5, were
synthesized. The peptides were evaluated for their ability to deliver two molecular cargos,
fluorescence-labeled cell-impermeable negatively charged phosphopeptide (F′-GpYEEI) and
fluorescence-labeled lamivudine (F′-3TC), intracellularly in human leukemia cancer (CCRFCEM) cells. We investigated the role of cyclization and the number of amino acids in improving
the transporting ability of the peptides. The flow cytometry studies suggested that the
synthesized peptides were able to work efficiently as transporters for both cargos. Among all
compounds, cyclic [CR]4 was found to be the most efficient peptide in transporting the cargo
into cells. For instance, the cellular uptake of F′-3TC (5 µM) and F′-GpYEEI (5 µM) was
enhanced by 16- and 20-fold, respectively, in the presence of cyclic [CR]4 compared to that of
the parent compound alone. The mechanism of F′-GpYEEI uptake by cells was found to be
energy-independent. The results showed that the number of amino acids and their cyclic nature
can impact the efficiency of the peptide in transporting the molecular cargos.
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The cell membrane is composed of a phospholipid bilayer.1
The bilayer forms an efficient barrier system between
intracellular and extracellular aqueous regions. Besides
phospholipids, there are also other components present in the
structure of the plasma membranes including glycolipids and
cholesterol. Several proteins in phospholipid bilayer are
responsible for selective transporting of cargos. Moreover, the
flexibility of the cell membrane is handled through an interaction
of double bonds and free fatty acid chains.2 The intracellular
delivery of highly hydrophobic, poorly water-soluble, and
negatively-charged compounds is a challenging task because of
the presence of negatively-charged phospholipid bilayer.
To enhance the intracellular concentration of cell impermeable
compounds, various classes of drug delivery systems (DDS) have
been developed and examined during last two decades.3 The
discovery and development of a new drug molecule are costly
and cumbersome. Thus, improving the cellular delivery of known
active compounds using DDS to enhance their biological activity
and/or offer controlled release or targeted delivery is a subject of
major interest.
Long-circulating macromolecular carriers, such as peptidebased molecules, can exploit the ‘enhanced permeability and
retention’ effect on the site of action.4 Among various classes of
peptide-based DDS, cell-penetrating peptides (CPPs) have been
broadly used due to their unique properties such as non-viral
nature, biocompatibility, and cell permeability into the plasma
membrane.5 The ability of CPPs has been examined for the
delivery of various types of cargos including small drugs 6-9 and
large-molecule based therapeutics.10

was critical for their function as molecular transporters and DDS.
Cyclic peptides also offer higher stability in serum compared to
the corresponding linear ones.16
Cysteine-rich peptides have been previous used as cellular
delivery agents.17 It has been previously reported that a cysteinerich decapeptide, named CyLoP-1 (Cytosol Localizing Peptide-1)
was able to cross the cell membrane readily. This cysteine-rich
peptide exhibited the potential for cytoplasmic distribution
besides vesicular localization and proficient cellular uptake at
low-micro-molar concentrations.17a Thus, cysteine appears to
contribute in peptide cell permeability.
Herein, we report the preparation of cyclic and linear peptides
containing an alternative sequence of cysteine and arginine
residues and their evaluation as intracellular molecular
transporters. We hypothesized that the presence of cysteine and
arginine residues would provide an appropriate combination of
amino acids for facilitating the cell permeability of the cargo
molecules.
Five cyclic and linear peptides containing alternative sequence
of cysteine and arginine amino acids namely c[CR]4, c[CR]5,
l(CR)3, l(CR)4, and l(CR)5 (Figure 1) were synthesized. Brackets
and parenthesis show cyclic and linear peptides, respectively.
The peptide synthesis was performed employing 9fluorenylmethyl oxycarbonyl (Fmoc)-based chemistry according
to our previously reported procedure.13,18

Positively charged amino acids such as arginine and lysine are
the main residues in the structure of the majority of CPPs. These
amino acids provide positive charges on the surface of CPPs and
facilitate electrostatic interactions with negatively charged
molecules, such as heparin and phospholipids within the cell
membrane.
In addition to the ability of CPPs to penetrate into the cell
membrane, the loading and release processes of molecular cargos
inside the cell are particularly important in the overall
functionality of the system. Thus, researchers tend to avoid
obstacles in loading and release processes by taking advantage of
non-covalent approaches. This method offers simple loading
procedure and smooth intracellular release of the intact cargo. 11,12
Technically, the sequence of amino acids can modify the
molecular interactions, such as electrostatic and hydrophobic
interactions between the cargo and the peptide. An optimized
orientation could improve the loading capacity of the system by
providing appropriate regions to entrap the molecular cargos.
Thus, a new arrangement of amino acids in peptide-cargo
complex can have an impact on the cell permeability and enhance
the drug uptake by cells.
Previously, we have reported the synthesis and evaluation of a
class of homochiral cyclic peptides with arginine and tryptophan
namely [WR]4 and [WR]5 as nuclear-targeting CPPs.13 These
peptides and peptide-capped gold nanoparticles showed a
significant efficiency to transport different cargos into cells.14,15
Our investigations revealed that the existence of a balance
between hydrophobic and positive charge properties of peptides

Figure 1. Chemical structures of synthesized peptides.
The synthesis procedure of linear l(CR)5 and c[CR]5 is shown
in Scheme 1 as representative examples. The linear peptide
containing ten alternative cysteine and arginine amino acids
(CRCRCRCRCR) was assembled on the heterogeneous HArg(Pbf)-2-chlorotrityl resin. The Fmoc group at the N-terminal
of the last coupled amino acid was deprotected using piperidine
in DMF (20% v/v) followed by capping using acetic anhydride.
The resin was washed and completely cleaved in the presence of
reagent
R
containing
TFA/thioanisole/1,2-ethanedithiol
(EDT)/anisole (90:5:3:2 v/v/v/v) to afford l(CR)5.

Scheme 1. Solid-phase synthesis of l(CR)5 and c[CR]5.

Circular dichroism (CD) was employed to compare the
secondary structure between the linear and cyclic peptides. Two
model peptides l(CR)5 and c[CR]5 were selected for this
investigation since they contain an equal number of amino acids.
All spectra were corrected for the baseline and the background by
subtraction of the blank. CD results showed that l(CR)5 (50 µM)
exhibited a different CD pattern when compared to that of c[CR]5
(50 µM).
l(CR)5 showed two minimum peaks at 204 and 228 nm,
suggesting that the carrier does not form a classic secondary
structure (Figure 2). However, the CD results of c[CR]5 showed a
pattern slightly different than a random-coil as shown by a
minimum at 210 nm. This has been reported that peptides
holding random coil secondary structure, show a maximum and a
minimum peak at ∼ 220 nm and ∼ 198 nm. This classic pattern
could be shifted due to several reasons including π-π* transition

of amide bond.19,20 These data suggest that although these two
peptides have similar number of amino acids, they form different
secondary structures. These results confirm that the cyclization
can change the conformation of the peptides.
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For the synthesis of the cyclic peptide, the peptide containing
protected side chain was cleaved from the trityl resin in the
presence of a cocktail composed of acetic acid/trifluoroethanol
(TFE)/dichloromethane (DCM) (1:2:7 v/v/v) at room
temperature. The side chain-protected linear peptide was used for
further cyclization reaction. To cyclize the linear peptide, 1hydroxy-7-azabenzotriazole (HOAt, 4 equiv) and 1,3diisopropyl- carbodiimide (DIC, 4.5 equiv) were used in a
mixture of DMF/DCM (5:1 v/v) solvents. The reaction was
performed for 12 h to obtain the protected cyclic peptide. After
the cyclization reaction was complete, the side chain protecting
groups were removed by using a cleavage cocktail reagent R
containing TFA/thioanisole/EDT/anisole (90:5:3:2 v/v/v/v) for 2
h to yield c[CR]5. Both crude peptides were precipitated using
cold diethyl ether (75 mL, Et2O). The purification of the peptides
was carried out by using reversed-phase Hitachi HPLC (L-2455)
on a Phenomenex Prodigy 10 µM ODS reversed-phase column
(2.1 cm × 25 cm). Pure peptides were obtained in the form of
white powder after lyophilization.
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Figure 2. CD spectra of l(CR) 5 and c[CR]5 at 50 µM.
The cytotoxicity of all synthesized peptides was evaluated in
human ovarian (SK-OV-3) and leukemia (CCRF-CEM) cancer
cells at different concentrations (50 and 100 µM) after 24 h
incubation time (Figure 3). None of the peptides showed
significant toxicity at 50 µM. However, among all peptides,
c[CR]5 was found to be more toxic compared to others as CCRFCEM and SK-OV-3 cells showed 78% and 82% viability,

respectively, in the presence of 100 µM of the peptide. No
significant difference in toxicity profile between linear and cyclic
peptides was observed at 50 µM showing that the cyclic nature
did not alter the cytotoxicity. Based on the cytotoxicity assay
results, the non-toxic concentration of 50 µM of peptides was
used for further cell-based studies.
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Figure 4. Cellular uptake of fluorescence-labeled F′-3TC (5 µM)
after 3 h incubation with cyclic and linear peptides.
As it is shown in Figure 4, the ring size of the peptide also
contributes to the delivery efficiency. Two cyclic peptides
namely c[CR]4 and c[CR]5 (50 µM) containing eight and ten
alternative arginine and cysteine residues were examined for their
ability to transport F′-3TC in a comparative assay. It was found
out that the cellular uptake of F′-3TC was increased in the
presence of c[CR]4 and c[CR]5 by 16 and 12-fold, respectively,
compared to that of the F′-3TC alone after 3 h of incubation.
These results indicate that although c[CR]4 is composed of less
number of amino acids compared to c[CR]5, it has a higher
ability to transport a fluorescence-labeled anti-HIV drug
presumably, possibly due to the optimal interactions with the
cargo and the phospholipid bilyaer.

20

Figure 3. Cytotoxicity assay of the peptides (50 and 100 µM) in
CCRF-CEM and SK-OV-3 cells after 24 h.

After a non-toxic concentration of peptides was determined,
all peptides were evaluated for their molecular transporting
activity. The effect of peptides on the intracellular uptake of
molecular cargos was examined using a flow cytometry method.
Two different model cargos, anti-HIV drug lamivudine, and
phosphopeptide GpYEEI were selected at a low concentration for
the cellular delivery investigations. Lamivudine ((–)-2′,3′dideoxy-3′-thiacytidine, 3TC) is a potent nucleoside reverse
transcriptase inhibitor that blocks HIV-1 and hepatitis B virus
replication. 21 However, this drug suffers from low cellular uptake
because of high polarity. Phosphopeptides have been used as
reagent probes to mimic phosphoproteins involved in signal
transduction pathway for protein−protein interactions.22,23
Although phosphopeptides are valuable probes, their use is
challenging in cellular studies due to their limited cellular uptake.
The cellular uptake of fluorescence-labeled 3TC (F′-3TC, 5
µM) was measured in the presence and absence of peptides (50
µM) in CCRF-CEM cells after 3 h. As it is shown in Figure 4,
the cellular uptake of F′-3TC was enhanced upon mixing with
l(CR)4, l(CR)5, c[CR]4, and c[CR]5 by 6-, 10-, 16-, and 12-fold,
respectively, compared to that of F′-3TC alone in CCRF-CEM
cells after 3 h of incubation. Among all tested peptides, l(CR) 3
did not enhance the cargo’s uptake, and c[CR]4 showed the
highest efficiency in improving the cellular uptake. These data
suggest that these peptides can be used as efficient transporters
for F′-3TC.
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Different results were obtained when comparing the linear
peptides l(CR)3, l(CR)4, and l(CR) 5. As shown in Figure 4, l(CR)5
improved the cellular uptake of F′-3TC by 10-fold. However,
l(CR)3 and l(CR)4 improved the cellular uptake of F′-3TC by only
0.5- and 6-fold, respectively. These data suggest that the higher
number of amino acids in linear peptides can enhance the
delivery efficiency of the linear peptides possibly because of a
greater number of positively-charged arginine residues. For
cyclic peptides, the orientation of peptides for efficient
interactions with cargo and the cell membrane appears to be the
critical factor in determination of the cellular uptake.
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Figure 5. Cellular uptake of fluorescence-labeled F′-GpYEEI (5
µM) after 3 h incubation with cyclic and linear peptides.
In order to investigate the potential of CR peptides to carry
other types of cargos, the cellular uptake of a fluorescencelabeled phosphopeptide namely F′-GpYEEI was examined in the
presence of the peptides and alone. The cellular uptake of F′GpYEEI in CCRF-CEM cells was improved by 4, 17, 20, and 18fold, respectively, when they mixed with l(CR)4, l(CR)5, c[CR]4,
and c[CR]5 compared with that of the phosphopeptide alone after
were 3 h incubation. As it was shown in Figure 5, l(CR)3 was
unable to enhance the cellular uptake of F′-GpYEEI possibly
because this number of positively-charged amino acids are not
sufficient for the delivery of molecular cargos into cells. It was
observed that c[CR]4 was again the most efficient among all
tested peptides, presumably due to the optimized interactions
with the cargo and the cell membrane. These results were
consistent with the data for the delivery of F′-3TC in the presence
of c[CR]4 as described above.
Determination of the mechanism(s) of the drug uptake by cells
has become important to optimize or design the next generation
of carriers. One of the major mechanisms of peptide-mediated
drug delivery is endocytosis. Endocytosis includes several

pathways such as micropinocytosis, phagocytosis, and receptormediated endocytosis (RME). RME also contain clathrinmediated, caveolae-mediated pathways.24
To get a better understanding of the internalization pathway,
the cellular uptake of F′-GpYEEI + c[CR]4 (5:50 µM) mixture
was tested in the presence of multiple endocytic inhibitors, such
as methyl-β-cyclodextrin (β-CD), chlorpromazine (CP), 5-(Nethyl-N-isopropyl)-amiloride (EIA), and chloroquine (Cq) in
CCRF-CEM cells. A similar incubation time (3 h) was used for
this assay.
As it is shown in Figure 6, the cellular uptake of F′-GpYEEI
was not changed significantly when CP and CQ were used.
However, in the presence of β-CD and sodium azide (NaN3), the
uptake was reduced by 20% and 19%, respectively. Sodium azide
is used to block the ATP production by oxidative
phosphorylation. This data suggest that the ATP depletion can be
responsible in the internalization process. Furthermore, β-CD
removes the cholesterol out of the structure of the cell membrane
and interferes with fluid phase and clathrin-mediated
endocytosis.25 Thus, these two pathways partially contribute for
the cellular uptake. The incubation of cells at 4 °C did not block
the uptake of the cargo.
1800

Mean of Fluorescence Intensity (a.u.)

1600
1400
1200
1000
800
600
400
200
0

Figure 6. Cellular uptake of F′-GpYEEI (5 µM) and c[CR]4 (50
µM) in the presence of endocytic inhibitors and sodium azide in
CCRF-CEM cells after 3 h.
We have previously used isothermal calorimetry (ITC) and
modeling techniques to investigate the interaction of cargos with
a similar class of cyclic peptides containing tryptophan and
arginine residues.13,26 The first step was the interaction between
the cargo (lamivudine or phosphopeptide) and the carrier peptide.
We have previously shown that electrostatic interactions between
the positively charged arginine in the structure of the peptide and
the negatively charged phosphate group in the structure of the
phosphopeptide. Furthermore, it was discovered that this class of
peptides could undergo self-assembly and aggregation in an
organized matter.27 Thus, drugs can be entrapped by the selfassembled structures. The second step was the interaction
between the carrier-cargo complex with the cell membrane. As
described in above, the arginine residues in the peptide provide
positive charges on the surface of CPPs and facilitate electrostatic
interactions with negatively charged phospholipids within the
cell membrane. Thus, it was expected that similar interactions to
occur between this class of peptides with cargo molecules and
cell membrane.
In conclusion, a new peptide-based carrier system composed
of cysteine and arginine was discovered for the delivery of an

anti-HIV drug and a cell impermeable phosphopeptide. The
cellular uptake of F′-GpYEEI and F′-3TC was enhanced in the
presence of these peptides. The number of amino acids, cyclic
nature, and ring size were found to contribute to the intracellular
delivery efficiency. These data confirm CPPs containing cysteine
and arginine residues as molecular transporters.
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